The pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP) is composed of cellular and humoral immunities. Macrophages might play a crucial role in cellular immunity. In addition, autoantibodies participate in the pathogenesis of CIDP. To date, various autoantibodies have been reported to affect peripheral nerve myelin. Although antibodies to glycolipids are frequently identified in Guillain-Barr e syndrome and closely related to the development of neuropathies, these are detected in only a small percentage of CIDP instances. Among glycolipids, sialosylneolactotetraosylceramide (LM1) is predominantly localized in human peripheral nerve myelin. LM1-related antibodies (e.g. anti-LM1, GM1/LM1 and GD1b/LM1 antibodies) are detected in some patients with CIDP and Guillain-Barr e syndrome. CIDP patients with those antibodies frequently present ataxia, but rarely have cranial nerve deficits; these features are associated with the localization of LM1, which is more abundant in the dorsal root than the cranial nerves. In immunoglobulin M paraproteinemic neuropathies, except for the anti-myelin-associated glycoprotein neuropathies, antibodies to glycolipids with disialosyl residues, such as GD1b and GQ1b, are also detected on occasion. Notably, this feature is clinically characterized by chronic ataxic neuropathy, ophthalmoplegia, immunoglobulin M paraprotein, cold agglutinins and disialosyl antibodies. Such clinical features are related to the localization of GD1b or GQ1b in human peripheral nerves. Overall, these correlations suggest a direct involvement of the antibodies in the pathogenesis of those aforementioned neuropathies.
Introduction
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a persistent or relapsing immunemediated neuropathy that is characterized by the progression of symmetrical weakness in both proximal and distal muscles for >2 months. Reportedly, the prevalence of CIDP is approximately 1-2 per 100 000 adult population, 1 and its pathogenic mechanism is related to both cellular and humoral immunities. 2 Several antibodies to glycoproteins, myelin proteins or glycolipids in peripheral nerves have been explored in immune-mediated neuropathies, such as CIDP, Guillain-Barr e syndrome (GBS), multifocal motor neuropathy (MMN) and immunoglobulin M (IgM) paraproteinemic neuropathies. Of these, the antibody to myelin-associated glycoprotein (MAG) was first identified in IgM paraproteinemic neuropathies in 1982; these IgM M-proteins were later reported to react with a sulfated glycolipid known as sulfated glucuronyl paragloboside. 3 In approximately 50% of patients with IgM paraproteinemic neuropathy, IgM M-proteins react with both MAG and sulfated glucuronyl paragloboside. Such neuropathy is known as anti-MAG neuropathy. GBS is an acute immune-mediated neuropathy, whose neurological symptoms worsen to nadir within a month. In 1988, Ilyas et al. identified anti-glycolipid antibodies in five of 26 patients with GBS for the first time. 4 Antibodies against glycolipids, which are localized in human peripheral nerves, are detected in nearly 60% of patients with GBS, with their pathogenic role in GBS being elucidated in the past 30 years.
In contrast to GBS, antibodies against glycolipids are detected in only a small subset of CIDP or other immune-mediated neuropathies. 5 Several studies, however, have highlighted various correlations between anti-glycolipid antibodies and clinical features in those neuropathies. The present review aims to discuss the pathogenic role and significance of the anti-glycolipid antibody, focusing on CIDP and IgM paraproteinemic neuropathies, excepting anti-MAG neuropathy.
Pathogenesis
In CIDP, several randomized control trials have established the effectiveness of plasma exchange, intravenous immunoglobulin and corticosteroids. [6] [7] [8] [9] [10] [11] Whereas corticosteroids suppress the production of cytokines by affecting T cells, plasma exchange removes humoral factors, such as autoantibodies. The reported effectiveness of immunotherapies suggests the correlation of both cellular and humoral immunities with the pathogenesis of CIDP.
Cellular immunity
Several studies investigating sural nerve biopsy of patients with CIDP have shown an infiltration of CD4-or CD8-positive T cells and macrophage into the nerves, especially the invasion of macrophages into the basal lamina of Schwann cells (macrophagemediated demyelination). [12] [13] [14] [15] [16] Activated T cells, which are induced by antigens presented by macrophages, cross the blood-nerve barrier. They activate macrophages by producing cytokines, such as interferon-c, tumor necrosis factor-a and interleukin-2. Finally, macrophages damage myelin or Schwann cells by phagocytosis and cytotoxic activities (Fig. 1) . 17 
Humoral immunity
In 1980, Dalakas et al. reported immunoglobulin and complement deposits on myelinated fibers of the sural nerves of patients with CIDP. 18 In addition, Yan et al. reported that serum or purified immunoglobulin G (IgG) from patients with CIDP caused conduction block and demyelination in rat nerves. 19 These findings substantially supported a crucial role of autoantibodies in the pathogenesis of a subset of CIDP. 20 
Figure 1
The putative immunopathogenesis of chronic inflammatory demyelinating polyneuropathy is shown. Nerve antigens are presented by antigen-presenting cells, such as macrophages. Activated T cells then produce cytokines that induce the production of autoantibodies in plasma cells. Activated T cells and autoantibodies cross the blood-nerve barrier. Autoantibodies bind to the antigens on peripheral nerves, and cause demyelination. In addition, autoantibodies induce the complement activation. Membrane attack complex (MAC), C5b-C9, causes demyelination and axonal damage by injuring the cell membrane of the peripheral nervous system. In contrast, macrophages invading into basal lamina of Schwann cells cause the damage of myelin and Schwann cells by phagocytosis and cytotoxic activities (macrophage-mediated demyelination).
Based on the the Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society guidelines of CIDP in 2010, CIDP is categorized into typical CIDP and atypical CIDP, including distal acquired demyelinating symmetric (DADS) and multifocal, acquired demyelinating sensory and motor neuropathy. 21 Whereas typical CIDP clinically presents with both proximal and distal muscle weakness, DADS presents with predominantly distal muscle weakness, thereby indicating a primary injury to the distal nerve terminals or nerve roots lacking the blood-nerve barrier. Assumedly, the antibody-mediated mechanism is possibly related to the pathogenesis of typical CIDP or DADS, because the neuropathy can be caused by antibodies that can easily cross these areas. 22 Glycolipid antibodies in Guillain-Barr e syndrome Glycolipids, which are preferentially localized in both the central and peripheral nervous systems, appear on the outer membrane of the lipid bilayer, and create lipid rafts along with cholesterol and glycosylphosphatidylinositol-anchored protein. Antibodies to glycolipids are often recognized in acute-phase sera of patients with GBS. In GBS, antecedent infectious agents comprise structures mimicking carbohydrate of glycolipids, and antibodies to glycolipids are produced by an immune response to antecedent infectious agents, such as Campylobacter jejuni, Haemophilus influenzae and Mycoplasma pneumoniae.
To date, antibodies against >10 glycolipids have been recognized in GBS; the distribution of each glycolipid antigen in human peripheral nerves is well correlated with clinical phenotypes of GBS cases with each antibody. 23 Additionally, in 2004, IgG antibody to glycolipid complex, a novel epitope created by the carbohydrate-carbohydrate interaction of two independent glycolipids, was identified in patients with GBS for the first time. 24 Cholera toxin, which is specific for monosialotetrahexosylganglioside (GM1), or monoclonal antibody binding studies have shown that GM1 is localized at the membrane of the nodes of Ranvier. 25, 26 Furthermore, GalNAc-GD1a is assumed to be present on the axonal membrane of the node of Ranvier. 27 Studies suggest that IgG antibody to GM1
or GalNAc-GD1a is closely related to acute motor axonal neuropathy as a subtype of GBS. 28, 29 In addition, IgG antibody to glycolipid complex consisting of GM1 and GalNAc-GD1a has been reported in acute motor conduction block neuropathy. 30, 31 Carbohydrate structures of GD1b, GD3, GT1b, GT1a and GQ1b comprise one or two disialosyl residue(s) containing a sequence of two sialic acids (Fig. 2) . In 1994, a study reported a patient with acute self-limiting ataxic neuropathy who had IgG antibodies to GD1b and GD3, but not to GT1a and GQ1b. 32 Since then, several cases with acute sensory ataxic neuropathy with IgG antibodies to GD1b alone or some of the glycolipids with at least one disialosyl residue, including GD1b, have been reported. 33, 34 GD1b is present in large neurons of dorsal root ganglia. 35 In 1996, a study reported the induction of sensory ataxic neuropathy in rabbits sensitized with GD1b. 36 In addition, it has been shown that monospecific GD1b IgG antibody is required for induction of the animal model, and two patients with acute sensory ataxic neuropathy comprising high titers of monospecific GD1b IgG antibody have been reported. 37, 38 After the discovery of anti-glycolipid complex antibodies, it has been shown that the specific GD1b antibody without reactivities to glycolipid complex is correlated with the development of sensory ataxia in GBS. 39 Of note, apoptosis of large neurons in dorsal root ganglia from an animal model has been reported as one of the mechanisms of GD1b antibody-associated sensory ataxic neuropathy. 40 
Sialosylneolactotetraosylceramide
(LM1) and galactocerebroside (Gal-C), which are major components of nerve myelin, are possibly target antigens in acute inflammatory demyelinating polyneuropathy (AIDP). In 1988, the IgG antibody against LM1 was one of the first identified anti-glycolipid antibodies in patients with GBS. 4 Yako et al. reported Figure 2 Carbohydrate structures of glycolipids with disialosyl residue, which consists of a sequence of two sialic acids, are shared by GD3, GD1b, GT1a, GT1b and GQ1b (shown by box lines).
that based on the electrophysiological examination, five of seven patients presenting with GBS with anti-LM1 IgG antibody were classified as AIDP. 41 In contrast, in 1979, it was reported that the sensitization of rabbits with Gal-C induces demyelinating neuropathy. It was the first animal model of neuropathy induced by individual glycolipid. 42 Often, antibodies to Gal-C localized at both peripheral nervous system (PNS) and central nervous system (CNS) myelin are detected in GBS or CNS diseases after M. pneumoniae infection. [43] [44] [45] Several studies have shown that M. pneumoniae comprises a component that mimics the carbohydrate structure of Gal-C. 46, 47 Based on electrophysiological studies, GBS cases with anti-Gal-C antibody are mostly classified as AIDP. 44, 45 In GBS, the subclass of anti-glycolipid IgG antibody is predominantly IgG1 or IgG3, which activates the complement. 48, 49 Several previous studies have shown the deposition of C3d or membrane attack complex consisting of C5b-C9, indicating complement activation on the nerves of patients with GBS. 50, 51 In addition, eculizumab, a humanized monoclonal antibody against C5, was proven to prevent respiratory paralysis in a murine neuropathy model induced by anti-GQ1b antibody, along with the suppression of the membrane attack complex deposition. 52 Therefore, eculizumab could be a potential novel treatment for GBS. 53 Glycolipid antibodies in chronic inflammatory demyelinating polyneuropathy Ogawa-Goto et al. showed the glycolipid composition of myelin isolated from the human PNS. In particular, GM1, GD3 and LM1 are major glycolipids in human motor nerve myelin (GM1 15%, GD3 18% and LM1 40%, respectively). 54 Thus, autoantibodies to those glycolipids that can be potential target antigens of CIDP have been investigated. However, the positive rates of these antibodies are lower in CIDP than in GBS.
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GM1 antibody
Reportedly, GM1, which is the primary ganglioside in the human CNS, is more enriched in human peripheral motor nerve myelin than in sensory nerve myelin. 54 IgM antibody to GM1 is detected in approximately 50% of MMN, which is characterized by motor conduction block without sensory nerve disturbance. 55 However, the pathogenic role of the antibody in MMN remains unclear.
Between the 1990s and 2000, several studies showed the detection of the antibody to GM1 in some patients with CIDP. In these studies, IgM or IgG antibody to GM1 were detected in 0-17% or 0-23% of patients with CIDP using enzyme-linked immunosorbent assay (ELISA) or thin layer chromatography (TLC). [56] [57] [58] [59] [60] In addition, recent research reports that 27.8% (5/18) or 5.6% (1/18) of patients with CIDP comprised IgM or IgG anti-GM1 antibody. 61 Antecedent infections are rarely observed in CIDP patients. However, Mel endez-V asquez et al. reported serological evidence of C. jejuni in 10% (4/ 40) of patients with CIDP. 56 Van Schaik et al. reported that neurological enhancements in patients with CIDP with a high titer of GM1 antibody before intravenous immunoglobulin were less than in those with a low titer. 59 Furthermore, a study has shown that sera from five anti-GM1 antibody-positive patients, including four with GBS and one with CIDP, suppressed Na + current more than those antibody-negative sera in rat myelinated fibers.
62
LM1 antibody
LM1 is the leading glycolipid in human PNS myelin, but not in CNS myelin. In 1991, Fredman et al. detected the anti-LM1 IgG antibody in 67% (13/15) of patients with CIDP, and 43% (10/23) of patients with GBS by ELISA and TLC. 63 In 1992, Ilyas et al., using ELISA and TLC, investigated antibodies to several glycolipids including LM1 in CIDP, GBS and other diseases, and detected IgM anti-LM1 antibodies in 13% (2/16) of patients with CIDP and IgG anti-LM1 antibodies in 21% (11/53) of patients with GBS. 57 Likewise, Yako et al. detected IgG anti-LM1 antibodies in 3% (1/33) of patients with CIDP and 5% (7/140) of patients with GBS. 41 These findings suggest that LM1 is the potential target antigen of demyelinating polyneuropathies, such as CIDP and GBS, because it is specifically localized to peripheral nerve myelin.
Of note, anti-glycolipid complex antibodies have been reported not only in GBS, but also in chronic immune-mediated neuropathies. 64 We focused our attention on glycolipid complexes containing LM1, the primary glycolipid in human PNS myelin, and reported the IgG antibodies to LM1-containing glycolipid complexes in CIDP and GBS in 2011. 65 Using ELISA, we examined LM1-related IgG antibodies (IgG antibody to LM1, GM1/LM1 or GD1b/LM1) in 40 patients with GBS, and 40 with CIDP. LM1-related IgG antibodies were identified in 25% (10/40; seven had IgG antibody to LM1, one had IgG antibody to GM1/LM1 and two had IgG antibody to GD1b/LM1) of CIDP, and 20% (8/40; five had IgG antibody to LM1 and three had IgG antibody to GM1/LM1) of GBS. The IgG reactivity to glycolipid complex containing LM1 was confirmed by not only ELISA, but also TLC (Fig. 3a) . Then, five of eight patients with GBS comprising LM1-related IgG antibodies were classified as having AIDP. GM1 is present in human myelin and the nodes of Ranvier. A previous immunohistochemical study showed the presence of GD1b in the paranodal myelin of human peripheral nerves. 35 Perhaps, LM1-containing glycolipid complexes (GM1/LM1 and GD1b/LM1), as well as LM1 itself, are potential target antigens in a subset of CIDP and AIDP because their distribution in the PNS suggests the formation of new epitopes by the interaction between LM1 and those glycolipids (Fig. 3b) .
After this analysis, we investigated the correlations between LM1-related IgG antibodies and clinical features of CIDP with those antibodies in 2013. 66 We examined LM1-related IgG antibodies in an additional 75 patients with CIDP, and these IgG antibodies were identified in 11% (8/75; LM1 antibody in two, GM1/ LM1 antibody in three, GD1b/LM1 antibody in one, and both GM1/LM1 and GD1b/LM1 antibodies in two). We compared the characteristics between 18 patients with LM1-related IgG antibodies and 97 CIDP patients without these antibodies, including patients from a previous study. LM1-related IgG antibodiespositive CIDP patients were significantly more elderly (68 vs 55 years, P < 0.05), developed ataxia more frequently (67% vs 32%, P < 0.01) and had fewer cranial nerve involvements (0% vs 21%, P < 0.05) than those in antibodies-negative CIDP patients.
A previous biochemical study of human peripheral nerves showed the relatively higher presence of LM1 in the dorsal root than in the cranial nerves. 67 Perhaps the characteristics of LM1-related IgG antibodies-positive patients with CIDP could be associated with the concentration of LM1 in each region. However, the pathogenic mechanism of these antibodies in CIDP remains unclear to date.
Disialosyl antibody
In 1985, using ELISA and TLC, Ilyas et al. reported the first patient with polyneuropathy related to paraproteinemia who had IgM reactivities to GD2, GD3, GD1b and GT1b, but not to GM1, GM3 and GD1a. 68 They showed the reaction of IgM paraprotein with those glycolipids. Although polyneuropathy patients with IgM disialosyl antibodies are rare, in 2001, Willison et al. investigated the clinical and laboratory characteristics of 18 patients who had been previously described as case reports. 69 These Figure 3 (a) Thin-layer chromatogram (TLC) immunostaining using a patient's serum shows the reactivity to only the overlapping portion of monosialotetrahexosylganglioside (GM1) and sialosylneolactotetraosylceramide (LM1) in lane 3, whereas reactivity to GM1 or LM1 alone is not observed in lane 1 or 2. The reactivity is considered as a specific antibody to GM1/LM1 complex. (b) Localizations of GM1, GD1b and LM1 in the peripheral nervous system (PNS) are shown. Those distributions suggest the possibility that new epitopes are formed by an interaction between LM1 and other glycolipids (GM1 or GD1b).
patients were characterized by chronic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl antibodies (CANOMAD). Furthermore, both electrophysiological studies and nerve biopsies showed demyelinating and axonal features. Antibody to GQ1b is a diagnostic marker for Fisher syndrome (FS) and GBS with ophthalmoplegia. 70 FS is characterized by ophthalmoplegia, ataxia and areflexia. GQ1b is localized at the paranodal myelin of the cranial nerves innervating extraocular muscles and large neurons of the dorsal root ganglia, and these localizations are strongly associated with clinical features of FS. 71 The distributions of GD1b and GQ1b in human peripheral nerves are well correlated with the clinical features of CANOMAD. In the paraproteinemic demyelinating polyneuropathies, IgM antibody to GD1b or GQ1b might have a pathogenic role, as well as IgG antibody to GD1b in GBS with ataxia and IgG antibody to GQ1b in FS.
Other glycolipid antibodies
Of glycolipids, sulfatide and Gal-C are primary components of nerve myelin. Sulfatide is a major acidic glycosphingolipid comprising sulfate epitope in myelin. In 1991, by using TLC, Fredman detected an anti-sulfatide antibody in 87% of patients with CIDP. 63 However, the antibody has also been observed in various diseases, such as multiple sclerosis. 72 Several studies have suggested a correlation between high titers of anti-sulfatide antibody and peripheral neuropathy. 56, 57, [73] [74] [75] Additionally, a previous study highlighted the association of high titers of the antibody with predominantly sensory or sensorimotor axonal neuropathies. Reportedly, IgM monoclonal gammopathy and elevation of IgM are often observed in anti-sulfatide antibody-positive patients. 75 Although anti-sulfatide antibody-associated neuropathies are relatively heterogeneous, the antibody might be related to IgM paraproteinemic neuropathies rather than CIDP. It is assumed that the IgM M-protein that reacts with sulfatide also reacts with sulfated glucuronyl paragloboside. Studies regarding antibody to Gal-C have been less frequently reported in CIDP than in GBS. In 1984, however, Hughes et al. detected antibody to Gal-C in 9% (1/11) of patients with CIDP, subsequent studies could not establish significant reactivities to Gal-C in CIDP. [76] [77] [78] As mentioned previously, however, Gal-C might be one of the target antigens in AIDP; whether it is a target antigen in a subset of CIDP is unclear.
A recent study reported IgM antibody to glycolipid complex comprising sulfatide and Gal-C in IgM paraproteinemic neuropathies. 79 Whereas antibody to sulfatide alone was detected in 38% (28/73) of IgM paraproteinemic neuropathies, antibody to that complex was detected in 49% (36/73) of the neuropathies. The reactivity to sulfatide/Gal-C is rarely detected in other neuropathies, and testing for both sulfatide and Gal-C in IgM paraproteinemic neuropathies possibly enhances the sensitivity compared with antibody to sulfatide alone.
Rinaldi et al. and Galban-Horcajo et al. recently examined numerous combinations of glycolipid complexes in GBS and MMN using the glycoarray method: a comprehensive assay of glycolipids and glycolipid complexes antibodies, and IgM antibody to GM1/Gal-C was identified as the most common antibody in patients with MMN. [80] [81] [82] Using the same assay, we investigated the comparison of IgM and IgG antibodies with 55 antigens, including 10 glycolipids and 45 glycolipid complexes comprising of their combinations in immune-mediated neuropathies. 83 GalNAc-GD1a-related IgM antibodies (antibodies to GalNAc-GD1a or glycolipid complexes comprising GalNAc-GD1a and another glycolipid) were detected in 37.5% (9/24) of MMN, whereas GM1-related IgM antibodies were detected in 50% (12/24) of MMN. Therefore not only GM1, but also GalNAc-GD1a is an important target antigen in MMN. Of nine patients with GalNAcGD1a-related IgM antibodies, six had IgM antibody to GM1/GalNAc-GD1a. IgG antibody to GM1/GalNAc-GD1a is correlated with acute motor conduction block neuropathy, as mentioned previously. 30, 31 Similar to the IgG antibody in acute motor conduction block neuropathy, IgM antibody to GM1/GalNAc-GD1a might have a pathogenic role for the development of conduction block in MMN.
Complement activation in chronic immunemediated neuropathies with glycolipid antibody
Activation of this complement has been observed in not only GBS, but also MMN. A previous study reported that patients with MMN comprising anti-GM1 IgM antibody face more severities than patients without this antibody, and the titers of the antibody correlate with Medical Research Council scores. 84 In addition, a recent study has reported that, in patients with MMN, there is a correlation between the activation of the complement system by IgM anti-GM1 antibody and the degree of muscle weakness and axonal loss. 85 Recently, a study has also detected IgM antibodies to glycolipids or glycolipid complexes in 35% (19/54) or 9% (5/54) of IgM paraproteinemic neuropathies. This study shows the in vitro activation of complement by IgM antibodies. 86 The subclass of IgG antibodies to glycolipids, such as GM1 and LM1, is yet to be determined in CIDP, however, and whether these antibodies cause the activation of complement on peripheral nerve myelin of patients with CIDP is unclear.
Conclusion
Various immune-mediated mechanisms are associated with the pathogenesis of CIDP. Humoral immunity plays an essential role in, at least, some subtypes of CIDP, such as typical CIDP and DADS. Recently, proteins localized at the paranode, such as neurofascin 155 and contactin-1, are notable as novel target antigens in CIDP. The anti-neurofascin 155 IgG4 antibody could be involved in the pathogenesis of CIDP; however, these antibodies are only detected in approximately 10% of all patients with CIDP. The body of literature considers that several autoantibodies, including anti-glycolipid antibodies and anti-glycolipid complex antibodies, are possibly associated with the pathogenesis of a specific subset of CIDP. Because the pathogenesis of CIDP is heterogeneous, further investigation regarding various antibodies to glycolipid or glycolipid complexes in a large number of CIDP is required in order to detect new antibodies. Determination of the IgG subclass of glycolipid antibodies and investigation of complement activation should be carried out to ascertain their involvement in resultant pathogenic mechanisms. 
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